News Tenpoint eyes presbyopia drug launch after FDA nod Tenpoint is set to join the US market for drugs to treat presbyopia, taking on rival therapies from AbbVie, Orasis, and LENZ with a dual-acting rival.
News Tenpoint raises $70m for vision loss therapies UK-headquartered start-up Tenpoint Therapeutics has reeled in a commendable $70 million in first-round financing that will be used to develop its cell-based therapies for
News Chinese trial backs base-editing drug for thalassaemia A landmark study in China has shown that a base-editing therapy developed by CorrectSequence achieved stellar results in beta-thalassaemia.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.